Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block
暂无分享,去创建一个
Jules C. Hancox | Christopher E. Dempsey | Dominic Wright | Charlotte K. Colenso | Richard B. Sessions | J. Hancox | R. Sessions | C. Dempsey | Dominic Wright
[1] Nicole Schmitt,et al. Local Anesthetic Interaction with Human Ether-a-go-go–related Gene (HERG) Channels: Role of Aromatic Amino Acids Y652 and F656 , 2005, Anesthesiology.
[2] M. Cadene,et al. X-ray structure of a voltage-dependent K+ channel , 2003, Nature.
[3] Liang Guo,et al. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. , 2005, Journal of pharmacological and toxicological methods.
[4] U. Zachariae,et al. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. , 2009, Journal of medicinal chemistry.
[5] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[6] Gert Vriend,et al. Toward a Consensus Model of the hERG Potassium Channel , 2010, ChemMedChem.
[7] P. Focia,et al. Structural basis of TEA blockade in a model potassium channel , 2005, Nature Structural &Molecular Biology.
[8] Pavel Jungwirth,et al. Specificity of ion-protein interactions: complementary and competitive effects of tetrapropylammonium, guanidinium, sulfate, and chloride ions. , 2009, The journal of physical chemistry. B.
[9] S. Heinemann,et al. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. , 1996, The Journal of physiology.
[10] Haruo Honjo,et al. Molecular determinants of hERG channel block by terfenadine and cisapride. , 2008, Journal of pharmacological sciences.
[11] Yumi N Imai,et al. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. , 2009, Journal of medicinal chemistry.
[12] Jules C. Hancox,et al. Interactions between Voltage Sensor and Pore Domains in a hERG K+ Channel Model from Molecular Simulations and the Effects of a Voltage Sensor Mutation , 2013, J. Chem. Inf. Model..
[13] Eduardo Perozo,et al. Structural mechanism of C-type inactivation in K+ channels , 2010, Nature.
[14] M. Jiang,et al. Differential Effects of Bupivacaine on Cardiac K Channels: Role of Channel Inactivation and Subunit Composition in Drug—Channel Interaction , 1998, Journal of cardiovascular electrophysiology.
[15] Yi H. Zhang,et al. Molecular determinants of hERG potassium channel inhibition by disopyramide. , 2012, Journal of molecular and cellular cardiology.
[16] Stefan A. Mann,et al. hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.
[17] Jyoti Chattopadhyaya,et al. Computational and NMR study of quaternary ammonium ion conformations in solution , 2002 .
[18] A. Brown,et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.
[19] J. Mitcheson,et al. Molecular determinants of high-affinity drug binding to HERG channels. , 2003, Current opinion in drug discovery & development.
[20] M. Sanguinetti,et al. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Antoine Daina,et al. Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization. , 2011, European journal of medicinal chemistry.
[22] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[23] P. Tarantino,et al. Effect of trazodone on hERG channel current and QT-interval. , 2005, European journal of pharmacology.
[24] M. Sanguinetti,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[26] Johannes Brussee,et al. Exploring Chemical Substructures Essential for hERG K+ Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues , 2009, ChemMedChem.
[27] Yang Li,et al. Novel insights into K+ selectivity from high resolution structures of an open K+ channel pore , 2010, Nature Structural &Molecular Biology.
[28] Elizabeth Yuriev,et al. Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.
[29] Henggui Zhang,et al. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome , 2009, Journal of molecular and cellular cardiology.
[30] Serdar Durdagi,et al. Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding , 2012, J. Chem. Inf. Model..
[31] Adriaan P IJzerman,et al. Understanding of Molecular Substructures that Contribute to hERG K+ Channel Blockade: Synthesis and Biological Evaluation of E‐4031 Analogues , 2012, ChemMedChem.
[32] Ingo Muegge,et al. Docking and Scoring , 2003 .
[33] Lu Chen,et al. A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..
[34] Youxing Jiang,et al. Crystal structure and mechanism of a calcium-gated potassium channel , 2002, Nature.
[35] Kaichiro Kamiya,et al. Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.
[36] Peter Wolschann,et al. In silico Analysis of Conformational Changes Induced by Mutation of Aromatic Binding Residues: Consequences for Drug Binding in the hERG K+ Channel , 2011, PloS one.
[37] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[38] M. Sutcliffe,et al. Drug block of the hERG potassium channel: Insight from modeling , 2007, Proteins.
[39] M. Sanguinetti,et al. hERG potassium channels and cardiac arrhythmia , 2006, Nature.
[40] Geoffrey Chang,et al. Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. , 2010, Trends in biochemical sciences.
[41] Martin Traebert,et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. , 2004, European journal of pharmacology.
[42] J. Richardson,et al. The penultimate rotamer library , 2000, Proteins.
[43] Michael C Sanguinetti,et al. Structural Determinants of HERG Channel Block by Clofilium and Ibutilide , 2004, Molecular Pharmacology.
[44] F. Österberg,et al. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.
[45] Michael C Sanguinetti,et al. Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.
[46] Robin Taylor,et al. Comparing protein–ligand docking programs is difficult , 2005, Proteins.
[47] D. E. Clark,et al. Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.
[48] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[49] Benoît Roux,et al. Mechanism of intracellular block of the KcsA K+ channel by tetrabutylammonium: insights from X-ray crystallography, electrophysiology and replica-exchange molecular dynamics simulations. , 2007, Journal of molecular biology.
[50] Jules C Hancox,et al. The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping , 2004, Molecular Pharmacology.
[51] Stanley Nattel,et al. Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.
[52] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[53] Thomas Stützle,et al. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..
[54] R. Cramer,et al. Validation of the general purpose tripos 5.2 force field , 1989 .
[55] Jamie I Vandenberg,et al. Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.
[56] Christopher E. Dempsey,et al. Complex ion effects on polypeptide conformational stability: chloride and sulfate salts of guanidinium and tetrapropylammonium. , 2011, Journal of the American Chemical Society.
[57] H. Duff,et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.
[58] A. Cavalli,et al. Computational design and discovery of "minimally structured" hERG blockers. , 2012, Journal of medicinal chemistry.
[59] A. Brown,et al. Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.
[60] B Attali,et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.
[61] Adriaan P IJzerman,et al. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. , 2013, Journal of medicinal chemistry.
[62] B. Chait,et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.
[63] R. Friesner,et al. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.
[64] J. Hancox,et al. Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs , 2008, British journal of pharmacology.
[65] Michael J Sutcliffe,et al. Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs , 2006, Molecular Pharmacology.
[66] Brian K Shoichet,et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.
[67] Jules C Hancox,et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.